Luma Vision, a Dublin, Ireland- and Munich, Germany-based developer of a novel four-dimensional (4D) cardiac imaging and navigation platform, raised $22M in Series A3 funding.
The round added participation from new investors Atlantic Bridge Growth Fund and Bayern Kapital, and was led by existing investors EQT Lifesciences, ABV Uni Fund and imec.xpand. The new funding adds to grants won earlier by LUMA Vision from the Irish government’s Disruptive Technologies Innovation Fund ($6 million) and the European Union’s EIC Accelerator ($3 million).
The company intends to use the funds to gain FDA clearance, prepare for U.S. commercialization and develop the next generations of its VERAFEYE platform for additional clinical applications in cardiology and beyond.
Led by CEO Fionn Lahart and CTO Christoph Hennersperger, Luma Vision (formerly known as OneProjects Ltd) is a medical device company that designs and develops an innovative 4D imaging and navigation end-to-end platform for cardiac applications to deliver data at the point of therapy. VERAFEYE™, a novel all-in-one 4D imaging and navigation platform with data-driven software applications designed for cardiology, uses a proprietary catheter sensor combined with advanced digital imaging and deep learning to provide high-resolution, 360-degree imagery of the beating heart and surrounding anatomy. VERAFEYE can be used with other catheters or systems during cardiac surgery and, with multiple applications in one platform, can provide all of the imaging guidance needed during cardiac surgery in real time without the need for external systems such as X-ray or CT.
VERAFEYE will provide cardiologists with accurate, precise and comprehensive anatomical data required to guide personalized patient therapy across a variety of diseases, such as atrial fibrillation, left atrial appendage closure and cardiac valve replacement.
The company was originally a spin out company from Bioinnovate Ireland and Trinity College Dublin.
FinSMEs
18/12/2023